Immunohistochemical analyses of FABP5 performed in normal, benign prostate tumor, and malignant prostatic tumor tissues revealed that over 70% of prostate cancers show increased levels of FABP5 (Adamson et al. 2003), Table 1. Here, FABP5 is linked to benign neoplasm of prostate.